CAS: 2257-09-2; 2-Isothiocyanatoethylbenzene

上下游产品

CAS号75-15-0 二硫化碳 | CAS号64-04-0 β-苯乙胺 | CAS号24954-65-2 Triethylammoniu... | CAS号96989-50-3 二-2-吡啶基 硫碳酸 | CAS号19457-11-5 phenethyl-dithi... | CAS号6160-65-2 1,1-硫代羰基二咪唑 | CAS号463-71-8 硫光气 | CAS号19457-13-7 ethyl 2-phenyle... | CAS号32315-10-9 三光气 | CAS号18085-24-0 N-(phenethyl)-N... | CAS号35653-54-4 1-苄基-3-苯乙基-2-硫脲 | CAS号6815-00-5 2-苯乙基硫脲 | CAS号66491-03-0 7-氨基-3,4-二氢异喹啉-... | CAS号1196-38-9 3,4-二氢异喹啉-1(2H)-酮 | CAS号21198-23-2 4-(Beta-苯乙基)-3-氨基硫脲 | CAS号15093-42-2 1-苯乙基-3-苯基-2-硫脲 | CAS号22245-96-1 7-硝基-二氢异喹啉-2-酮 | CAS号76609-57-9 1-[(3-methyl-4-... | CAS号6552-60-9 1,2,3,4-四氢异喹啉-1-硫酮 | CAS号66491-04-1 7-碘-3,4-二氢异喹啉-1...

2-苯乙胺盐酸盐置于1-丙基磷酸酐体系中,用 二氯甲烷,乙酸乙酯 用作溶剂,化学反应 3.58H,反应生成2-苯基乙基异硫代氰酸酯
参考文献:T3P®-异硫氰酸酯合成中的良性脱硫试剂
标题:T3P®-异硫氰酸酯合成中的良性脱硫试剂
摘要:摘要 在母体伯胺或其盐与二硫化碳的两步一锅反应中,以中等至高收率(41-94%)获得了许多烷基,芳基和双官能异硫氰酸酯.与t3P形成二硫代氨基甲酸酯®(丙烷膦酸酐)作为一种新的和有效的脱硫剂. 在母体伯胺或其盐与二硫化碳的两步一锅反应中,以中等至高收率(41-94%)获得了许多烷基,芳基和双官能异硫氰酸酯.与t3P形成二硫代氨基甲酸酯®(丙烷膦酸酐)作为一种新的和有效的脱硫剂.
Doi:10.1055/s-0036-1591842

专利信息

专利号:WO-2017046598-A1
优先权日:2015-09-16
标题:Treatment of acute inflammatory disorders
发明人：CRISANTI ANDREA; CANAVESE MIRIAM
权利人:CRISANTI ANDREA; IMP INNOVATIONS LTD
摘要:The present invention relates to a VEGF receptor agonist for use in the treatment of an acute inflammatory disorder associated with the overproduction of pro-inflammatory cytokine, administered with an agent that induces the synthesis of Nrf2. The invention also relates to pharmaceutical combinations comprising a VEGF receptor agonist and an agent that induces the synthesis of Nrf2, and kits comprising these agents. The described uses, combinations and methods may prevent or reduce the dis-regulated activation of an inflammatory response and reduce endothelial damage.

专利号:US-2006078533-A1
优先权日:2004-10-12
标 题:Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
发明人：OMOIGUI OSEMWOTA S
权利人:OMOIGUI OSEMWOTA S
摘要:This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway.

专利号:US-2006275294-A1
优先权日:2002-08-22
标题:Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
发明人：OMOIGUI OSEMWOTA S
权利人:OMOIGUI OSEMWOTA S
摘要:This invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and/or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway

专利号:US-9168237-B2
优先权日:2011-12-06
标题:Adamantyl derivatives as therapeutic agents
发明人：MOORE RICHARD G; SINGH RAKESH K
权利人:WOMEN & INFANTS HOSPITAL OF RHODE ISLAND
摘要:The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis.

专利号:CN-106518743-A
优先权日:2016-10-28
标 题 :Synthesis of beta-phenethyl isothiocyanate

专利号:US-6166003-A
优先权日:1999-02-17
标 题 :Heterocyclic compounds for cancer chemoprevention
发明人：LAM LUKE K T
权利人:LKT LAB INC
摘要:A compound comprising a heterocyclic moiety, such as a thiophene, covalently attached to an alkylene isothiocyanate moiety. The compound is effective to prevent the occurrence or progression of cancer or a precancerous condition, and can be used for therapeutic or prophylactic purposes. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis and use of the chemopreventive compound of the invention are also provided.